Limoneira Co. (LMNR) Jumps 6.03% on January 20

Equities Staff |

Limoneira Co. (LMNR) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 6.03% to $12.66, representing a gain of $0.72 per share. Some 22,955 shares traded hands on 265 trades, compared with an average daily volume of 50,330 shares out of a total float of 14.15 million. The stock opened at $11.76 and traded with an intraday range of $12.66 to $11.64.

After today's gains, Limoneira Co. reached a market cap of $179.14 million. Limoneira Co. has had a trading range between $24.22 and $11.43 over the last year, and it had a 50-day SMA of $15.36 and a 200-day SMA of $18.78.

The stock has a P/E Ratio of 26.

Limoneira Co is engaged in growing citrus and avocados, picking and hauling citrus, and packing, marketing and selling lemons. The Company is also indulged in housing rentals and other rental operations and real estate development activities.

Limoneira Co. is based out of Santa Paula, CA and has some 333 employees. Its CEO is Harold S. Edwards.

For a complete fundamental analysis analysis of Limoneira Co., check out’s Stock Valuation Analysis report for LMNR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…